secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2026-08-05T10:27:37+00:00
Accession:  0001739104-26-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q2 revenue up 10% to $1.37B; raises full-year guidance on innovation momentum
--------------------------------------------------------------------------------

- Q2 revenue $1,368M (+10% YoY); organic constant currency growth 8%.
- Adjusted EPS $0.34 (+31% YoY); reported EPS $0.11 vs $0.02.
- Full-year 2026 guidance raised: revenue $5.09B-$5.14B, Adj EBITDA $1.01B-$1.035B, Adj EPS $1.10-$1.16.
- Innovation revenue target raised to $1.25B; net leverage ratio improved to 3.1x, targeting ~3.0x year-end.
- Pet Health revenue +12% driven by Zenrelia and Credelio Quattro; Farm Animal +9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/0001739104-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elan-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001739104-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer